Vycor Med Stock Price, News & Analysis
Company Description
Vycor Medical, Inc. (VYCO) is a corporation organized in the state of Delaware and subject to the reporting requirements of the Securities Exchange Act of 1934. The company files periodic and current reports with the U.S. Securities and Exchange Commission (SEC) under Commission File Number 001-34932 and federal tax identification number 20-3369218, as disclosed in its Form 8-K filing.
According to a Form 8-K dated November 14, 2025, Vycor Medical, Inc. reported information related to its results of operations and financial condition for the three- and nine-month periods ended September 30, 2025. This information was furnished under Item 2.02 of Form 8-K, which covers results of operations and financial condition. The filing specifies that the information provided under this item, and the related exhibit, is furnished rather than filed for purposes of Section 18 of the Exchange Act.
The same Form 8-K notes that Vycor Medical, Inc. issued a press release on November 14, 2025, discussing its financial results for the referenced periods. That press release is identified as Exhibit 99.1 to the Form 8-K. The company indicates that it uses both GAAP and non-GAAP financial measures when discussing its operating performance.
Use of Non-GAAP Financial Measures
In the Form 8-K, Vycor Medical, Inc. explains that it makes reference to non-GAAP financial information in its press release. Specifically, the company identifies non-GAAP Cash Operating Expenses and non-GAAP Cash Operating Loss measures. These non-GAAP measures exclude depreciation and non-cash stock compensation from the comparable GAAP financial measures.
The company states that management uses these non-GAAP measures to conduct what it considers a more meaningful and consistent comparison of ongoing operating results and trends, both against historical periods and against internally developed targets. Vycor Medical, Inc. also acknowledges that non-GAAP financial measures have limitations, including that they are not prepared in accordance with GAAP and may differ from similarly titled measures used by other companies.
The Form 8-K emphasizes that investors and potential investors should consider the non-GAAP financial measures only together with the company’s consolidated financial statements prepared in accordance with GAAP, as well as the reconciliations of non-GAAP to GAAP measures provided in the press release.
Regulatory Reporting and Investor Information
Vycor Medical, Inc. provides its financial information to the market through SEC filings, including current reports on Form 8-K. The November 14, 2025 Form 8-K illustrates how the company communicates quarterly financial results and the way it supplements GAAP results with non-GAAP metrics. The filing also includes an Exhibit 104 reference for the cover page interactive data file embedded within the Inline XBRL document, which is part of the SEC’s structured data requirements.
Because the available information is drawn from a specific Form 8-K, detailed descriptions of the company’s industry, products, services, and business model are not provided in that filing. Investors seeking a fuller understanding of Vycor Medical, Inc.’s operations typically review its annual reports on Form 10-K, quarterly reports on Form 10-Q, and additional current reports on Form 8-K, along with any related exhibits that discuss its activities in more detail.
Summary of Available Public Information
Based on the referenced Form 8-K, Vycor Medical, Inc. can be characterized as:
- A Delaware corporation that files reports with the SEC under File Number 001-34932.
- A company that communicates financial results through press releases furnished as exhibits to Form 8-K.
- An issuer that uses both GAAP and specified non-GAAP financial measures, including non-GAAP Cash Operating Expenses and non-GAAP Cash Operating Loss, with reconciliations provided in its press releases.
- An SEC registrant that presents interactive data for its cover page through Inline XBRL, as indicated by Exhibit 104.
Further details about its sector, industry classification, and specific business activities are not contained in the provided Form 8-K excerpt and would need to be obtained from other SEC filings or company disclosures.
Stock Performance
Vycor Med (VYCO) stock last traded at $0.0900. Over the past 12 months, the stock has gained 32.4%. At a market capitalization of $3.0M, VYCO is classified as a micro-cap stock with approximately 33.4M shares outstanding.
Latest News
SEC Filings
Vycor Med has filed 4 recent SEC filings, including 2 Form 8-K, 1 Form 10-K, 1 Form 10-Q. The most recent filing was submitted on March 31, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all VYCO SEC filings →
Financial Highlights
Vycor Med generated $1.9M in revenue over the trailing twelve months, retaining a 83.8% gross margin, operating income reached $34K (1.8% operating margin), and net income was -$72K, reflecting a -3.9% net profit margin. Diluted earnings per share stood at $-0.01. The company generated -$13K in operating cash flow.
Upcoming Events
Short Interest History
Short interest in Vycor Med (VYCO) currently stands at 834 shares, up 1000.0% from the previous reporting period, representing 0.0% of the float. Over the past 12 months, short interest has decreased by 80.8%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Vycor Med (VYCO) currently stands at 1.0 days, down 11.5% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 12.4 days.
VYCO Company Profile & Sector Positioning
Vycor Med (VYCO) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the OTC Link.